Adherence Gap Highlights Cost Divide
The PURPOSE 5 trial showed 85.6% of participants stayed on the twice‑yearly lenacapavir injection for a full year, compared with 46.3% persistence on daily F/TDF pills in the United Kingdom and France. Zero HIV infections occurred in the injection arm, while one infection was recorded in the pill arm, linked to low drug levels.
Wholesale Acquisition Cost Breakdown
Administered twice annually, the figure that matters for payers is $42,250 per patient per year. By contrast, the WAC for generic TDF/FTC oral PrEP hovers around $60 annually.
Access Programs and Insurance Landscape
Medicaid must cover FDA‑approved PrEP without cost‑sharing under the ACA preventive services mandate. No generic lenacapavir is approved for U.S. sale, and the only FDA tentative approval for a generic version applies to 120 low‑ and middle‑income countries.
Global Pricing Contrast
Dr. Reddy’s Laboratories, under a voluntary licensing agreement with Gilead, projects a $40‑per‑year price for two generic lenacapavir injections in the licensed countries. The agreement limits sales to the 120 resource‑limited nations and does not affect U.S. pricing.
Budget Impact Considerations
The higher adherence rate could reduce downstream HIV treatment costs, but the bottom line remains a steep price gap that insurers and uninsured individuals must absorb.
What It Means for Patients
Uninsured individuals meeting income criteria can receive lenacapavir at no charge through Gilead’s program, but eligibility is limited. Without such assistance, the $42,250 price tag is prohibitive for most Americans.
Next Steps
Gilead has submitted a once‑weekly oral formulation of lenacapavir for FDA review, aiming to expand options beyond the injection. Meanwhile, the FDA’s tentative approval of a generic version for LMICs underscores the stark contrast between U.S. pricing and global access strategies.
Sources
- Lenacapavir PrEP: 86% Stuck With the Shot, 46% With Pills
- Lenacapavir
- U.S. FDA approves first generic injectable lenacapavir for HIV prevention
- FDA Approves First Generic Of HIV Prevention Drug, Lenacapavir – Health Policy Watch
- FDA Tentatively Approves First Generic Lenacapavir PrEP for 120 LMICs | Contagion Live
- Positive new data for twice-yearly lenacapavir in HIV prevention
Photo: NutraSeller Manufacturing / Unsplash (Unsplash License)
